Opto-electrical coherence detection of hemodynamically compromising arrhythmia

Abstract

System and methods for assessing sensed signals for determining a reliability measure of their accuracy with respect to a patient's true physiological status. As one example, the signals can include multiple, independently obtained signals, such as an electro-chemically based measure of cardiac activity and a plethysmography based measure of hemodynamic output which typically exhibit different morphologies and varying phase shifts with respect to each other. One manner of assessing the signals is to transform them into the frequency domain, such as via a Fast Fourier Transform (FFT), and evaluate them, such as by a coherence determination, to determine the degree of their mutual agreement. This can be used to assess the reliability of the sensing. Therapy can be delivered under certain observed conditions, such as a condition of hemodynamic insufficiency where anti-tachycardia pacing and / or shocking therapy can be delivered.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application is a division of U.S. patent application Ser. No. 10 / 927,971, filed Aug. 26, 2004, titled “Opto-Electrical Coherence Detection of Hemodynamically Compromising Arrhythmia.”FIELD OF THE INVENTION[0002]The invention relates to the field of implantable medical devices and, more particularly, to methods and system for evaluating sensors to determine a confidence measure of their output to improve delivery of therapy and accuracy of sensing patient conditions, such as hemodynamic insufficiency.DESCRIPTION OF THE RELATED ART[0003]Hemodynamic output refers to the volumetric output of blood pumped by the heart over time. Failure to pump an adequate volume of oxygenated blood at an adequate rate to support the patient's metabolic needs is referred to as hemodynamic compromise or hemodynamic insufficiency. Hemodynamic insufficiency can arise from a variety of causes including bradycardia involving an insufficient heart rate, insuffi...

AI Technical Summary

Benefits of technology

The patent describes an implantable cardiac stimulation device that can adjust the delivery of therapeutic stimulation to the heart based on signals from sensors monitoring the patient's cardiac activity and other physiological parameters. The device can evaluate the signals and determine if they are related to each other, and use this information to adjust the therapy delivery. This allows for a more effective and targeted treatment of the patient's condition. The device can also correlate the signals to better understand the patient's physiological response and make appropriate therapy delivery decisions. Overall, the device can self-monitor the signals and make informed therapy delivery decisions based on the reliability of the signals being provided by the sensors.

Problems solved by technology

Hemodynamic insufficiency can arise from a variety of causes including bradycardia involving an insufficient heart rate, insufficient cardiac output per cardiac cycle, such as arising from weakened cardiac tissue resulting in a lowered ejection volume and / or ejection fraction, as well as systemic obstructions or restrictions limiting blood flow.

While these methods can provide a direct measurement indicative of the volumetric blood flow over time or hemodynamic output, they are subject to disruptive influences particularly when employed as sensors fixed to or implanted in a patient outside a clinical setting where there is often a greater likelihood of disruptions which can disturb their sensing so as to provide erroneous signals which degrades their reliability for providing a true indicator of the patient's instantaneous hemodynamic output.

In particular, these sensors are measuring volumetric or pressure changes over time and thus are subject to mechanical disturbances which can cause variations in the volumetric or pressure measurements as sensed by the sensor but which may not have a true relation to the patient's actual hemodynamic output.

However the aforementioned difficulties in employing a PPG sensor as a reliable indicator of hemodynamic output have limited the use of such sensors for diagnosis and initiation of therapy delivery, particularly with implantable medical devices in active patients outside a clinical setting.

A particular concern is in a tachycardia condition where the IEGM and / or ECG signals indicate an elevated heart rate but which in certain circumstances, either through reduced pumping efficiency and / or lack of coordination among the chambers of the heart, an elevated heart rate can occur with a reduced hemodynamic output leading to hemodynamic insufficiency.

However the aforementioned difficulties with direct measures of hemodynamic output, such as pressure and PPG sensors, have limited the effectiveness of such measures.

There are also difficulties with the reliability of other types of physiological parameter sensing, such as direct nerve sensing (e.g. phrenic or vagus nerve sensing) or sensing of cardiac activity in a noisy background.

Thus, there is a difficulty in reliably establishing a signal as corresponding to the physiological process and not noise.

Another difficulty in the reliability of sensed signals is that, in certain applications, sensing with multiple sensors can encounter sensing time lags or phase shifts that can vary over time, thus complicating the evaluation of one signal in relation to another.

Thus, while one or more sensors may be capable of providing more accurate and / or reliable data than others, a direct comparison to make this determination is frequently not readily feasible.

Images